From molecular glue discovery to the development of degrader-antibody conjugates, pharma is transforming through strategic transactions and by leveraging protein degradation technologies to expand target discovery and drug previously ‘undruggable’ targets.
Join the TPD & Induced Proximity Pharma Partnering Summit to accelerate partnership interest in your protein degradation pipeline or platform, by hearing first-hand:
- What: What are pharma’s targets of interest, and what data is sparking or prohibiting deal-making across TPD?
- Who: Who is the right person at each pharma, specifically for induced proximity assets?
- How: How are pharma analyzing data for a research collaboration versus a licensing deal?
Secure your place here or get in touch with the team – info@hansonwade.com